Skip to content

In primary membranous nephropathy, obinutuzumab increased the likelihood of complete remission vs. tacrolimus at 104 wk.

Oct 2026 · Annals of Internal Medicine · Vol 179, pp. JC114 · 0 citations · 1 references
Medicine

Abstract

CLINICAL IMPACT RATINGS GIM/FP/GP: [Formula: see text] Nephrology: [Formula: see text].

View source

Similar papers

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.